Showing 1701-1710 of 2192 results for "".
- Mild Cognitive Impairment: Where Does it Fit In?https://practicalneurology.com/columns/practice-management/mild-cognitive-impairment-where-does-it-fit-in/31043/Summary:Mild Cognitive Impairment (MCI) has gained prominence in the neurological landscape, particularly in the digital age where awareness spreads rapidly. MCI represents a crucial intermediary stage between normal age-related cognitive decline and more severe dementias, such as Alzheimer’s diseas
- Editor's Messagehttps://practicalneurology.com/columns/practice-management/editors-message/31050/Deep Brain Stimulation (DBS) Uncovers Potential in Memory RestorationA recent groundbreaking study published in the *Annals of Neurology* has highlighted the unexpected capabilities of Deep Brain Stimulation (DBS) in enhancing memory retention. Traditionally utilized for managing movement disorders
- Advancements in Epilepsy Syndrome Diagnosis and Managementhttps://practicalneurology.com/diseases-diagnoses/epilepsy-seizures/pn0208-epilepsy-dept-pdf/31051/Advancements in Epilepsy Syndrome Diagnosis and ManagementEpilepsy, one of the most historically recognized neurological disorders, remains the second most prevalent neurological condition, affecting approximately one percent of the global population. In the United States and Europe, new epilepsy ca
- Pain Managementhttps://practicalneurology.com/diseases-diagnoses/headache-pain/pn0208-pain-management-pdf/31054/Reevaluating NSAIDs in Low Back Pain ManagementA recent study highlighted in Practical Neurology challenges the prevailing use of non-steroidal anti-inflammatory drugs (NSAIDs) for managing low back pain (LBP). Conducted by Dr. Charles Argoff, the research indicates that NSAIDs offer no significant
- When Life Is "Fragrance-Free" — Taste & Smell Disorders In Clinical Neurologyhttps://practicalneurology.com/columns/practice-management/when-life-is-fragrance-free-taste-smell-disorders-in-clinical-neurology/31067/Taste and Smell Disorders: Emerging Concerns in Clinical NeurologyTaste and smell disorders are increasingly recognized within clinical neurology, expanding beyond their traditional focus in otorhino-laryngology. Dr. Ronald Devere underscores the rising prevalence of these sensory impairments in var
- Therapeutics Q&Ahttps://practicalneurology.com/columns/practice-management/therapeutics-qa/31068/Secondary Stroke Prevention: Optimizing Therapy Through Efficacy, Cost, and Risk ManagementEffective secondary stroke prevention remains critical in reducing recurrent cerebrovascular events. Leading neurologists emphasize a multifaceted approach primarily involving antiplatelet agents, antihyperten
- News Briefshttps://practicalneurology.com/columns/practice-management/news-briefs/31065/Recent studies highlighted in Practical Neurology’s January 2008 issue provide significant insights into neurological conditions and their broader health implications. Notably, research published in Neurology reveals that patients with Restless Legs Syndrome (RLS) face double the risk of stroke and
- Epilepsy Essentialshttps://practicalneurology.com/diseases-diagnoses/epilepsy-seizures/pn0108Epilepsy-pdf/31069/Predicting Seizures: Enhancing Epilepsy Management through Clinical InsightsEpilepsy remains a challenging neurological disorder, primarily due to the unpredictability of seizure occurrences. Despite the widespread use of anti-epileptic drugs (AEDs), approximately 40% of patients continue to experie
- Vascular Clinichttps://practicalneurology.com/columns/practice-management/vascular-clinic/31087/Establishing a successful hospital-based stroke program critically depends on unwavering support from hospital administration, a key requirement for Joint Commission on Accreditation of Healthcare Organizations (JCAHO) primary stroke center certification. In his December 2007 article for Practical N
- News Briefshttps://practicalneurology.com/columns/practice-management/news-briefs/31118/Recent advancements in neurology highlight significant progress and emerging insights into Alzheimer’s disease (AD) and related neurological conditions. A pivotal study published in the FASEB Journal reveals that amyloid β-derived diffusible ligand (ADDL) in AD patients disrupts insulin signaling by